Histopathological Grade versus Hormone Receptor Status in Breast Carcinoma- Treasure The Past

Geethamala K*1, Srinivasa Murthy V2, BR Vani2 and Sudha Rao2

1Department of Pathology, Kamineni Institute Of Medical Sciences, Narketpally, Nalgonda dist. India
2Department of Pathology, ESIC Medical College and PGIMSR, Rajajinagar, Bangalore, India

*Correspondence Info:
Dr. Geethamala K,
Assistant Professor
Department of Pathology,
Kamineni Institute of Medical Sciences,
Narketpally, Nalgonda dist. India
E-mail: drgeethamala@gmail.com

Abstract
Introduction: Breast carcinoma is the most common cancer among women. Prognosis and management of breast cancer are influenced by classic variables such as grade, stage, hormone receptor status of estrogen (ER), progesterone (PR) & Her2/neu overexpression. Though hormone receptor analysis is a prerequisite in this era, for management and prognosis, still histopathological grading can be taken up as an important variable for predicting prognosis. An attempt has been made in this study to correlate histopathological grade with hormone receptor status in breast carcinomas in our institution.

Objectives: To correlate the Histopathological grade with ER, PR and Her2/neu receptor status of breast carcinoma

Materials & Methods: A prospective study conducted from June 2011 to June 2014 in the department of Pathology, ESIC Medical College & PGIMSR, ESIC Model Hospital, Rajajinagar, Bangalore. Hundred Modified radical mastectomy specimens were subjected for routine histological examination and Immunohistochemical analysis. Clinical details were archived from the files. Statistical analysis was done and p value of <0.05 were taken as significant using chi-square test.

Results: The age of the patients ranged from 24 to 75 years. Majority of tumours were predominantly of histopathological grade two. By Immunohistochemistry 52% were ER+/PR+, 25% were Her2/neu positive and 20% of triple negatives. A significant association was seen between histologic grade and hormone receptor status.

Conclusion: Histologic grading together with receptor status offers an excellent method of correlation of survival rate and response to hormonal therapy which lightens up a prospect of various treatment modalities.

Keywords: Breast carcinoma, histologic grading, hormone receptor status.

1. Introduction
Breast carcinoma is the most common cancer among women in the urban Indian population and second only to cervical cancer in the rural population based on cancer registry data [1-3]. Prognosis and management of breast cancer are influenced by classic variables such as grade, stage, hormone receptor status of estrogen (ER), progesterone (PR) & Her2/neu overexpression[4-8]. Few Studies have found consecutive decrements of ER, PR expression as a measure of differentiation of the tumour with grade I (well differentiated) having the highest and grade III (poorly differentiated) having the lowest ER/PR expression. Her 2/neu over expression is associated with poor histologic grade so also the triple negative breast carcinomas. [4-8]

Though hormone receptor analysis is a prerequisite in this era, for management and prognosis, still histopathological grading can be taken up as an important variable for predicting prognosis. [4-8] Carcinomas with ER/PR positivity have a good prognosis as compared to carcinomas with ER/PR negativity. Also the histological grade has a bearing on the prognosis, as high grade have poor prognosis and vice versa,[4-12] An attempt has been made in this study to correlate histopathological grade with hormone receptor status in breast carcinomas in our institution.
1.1 Objectives
To correlate the Histopathological grade with ER, PR and Her2/neu receptor status of breast carcinoma

2. Materials & Methods
A prospective study conducted from June 2011 to June 2014 in the department of Pathology, ESIC Medical College & PGIMSR, ESIC Model Hospital, Rajajinagar, Bangalore. Hundred Modified radical mastectomy specimens were subjected for routine histopathological examination and Immunohistochemical analysis. Clinical details were archived from the files. Specimens were routinely fixed 24-48 hours in 10% neutral buffer formalin. They were examined grossly and representative tissue bits were taken according to standard guidelines and then processed. Sections were stained with routine hematoxylin and eosin (H&E) stain. Histopathological features were determined.

100 breast carcinomas diagnosed as infiltrating ductal carcinomas were histologically graded according to Modified Bloom–Richardson–Elston grading system. Representative sections with tumor and adjacent normal breast tissue (internal control) were further processed for IHC using Peroxidase-antiperoxidase (PAP) technique. Sections were taken on silane coated slides. Antigen retrieval was done by pressure cooker using EDTA buffer solution and slides stained with Monoclonal antibodies obtained from “Scytec” company. ER (mouse monoclonal clone 1D5), PR (mouse monoclonal clone PR88) Her2/neu (rabbit monoclonal clone EP1045Y). 500 cells on tissue sections were counted for positivity. ER, PR positivity was denoted by nuclear staining using Allred scoring system which takes into account both intensity of staining and proportion of positive tumour cells. ASCO (American Society of Clinical Oncology) guidelines 2007 denoting cytoplasmic membrane staining was used for Her2/neu grading.

2.1 Statistical analysis
The data was analyzed using SPSS software version 18.0. Obtained parameters were evaluated using descriptive statistical analysis and presented in terms of percentage. Association of patient’s age, tumor grade, tumor stage and hormone receptor status were tested with chi-square test. A p value of <0.05 were taken as significant.

3. Results
In the present study female patients with breast carcinoma were aged between 3rd and 7th decade of life. The youngest was 24 years and oldest 75 years. Majority (76%) were in 3rd and 4th decade of life. Left breast (50%) was marginally more affected than right side (49%) of breasts and in a single cases both breasts (1%) were affected. The commonest grade was grade 1 accounting to 54% followed by grade 2 and 3 with 27% and 19% respectively (Table 1) (Fig 1).

Table 1: Histopathological grading of breast carcinoma

| Grade of The Tumor | Frequency | (%)  |
|--------------------|-----------|------|
| 1                  | 19        | 19.0 |
| 2                  | 54        | 54.0 |
| 3                  | 27        | 27.0 |
| Total              | 100       | 100.0|

Fig 1: H&E showing (a) grade 1 (10x) (b) grade 2(10x) (c) grade 3(40x)
Table 2: IHC Hormone Receptor Status in breast carcinoma

| Hormone Receptor Status | Frequency | %   |
|-------------------------|-----------|-----|
| ER+/PR+                 | 52        | 52  |
| ER+/PR-                 | 2         | 2   |
| ER-/PR+                 | 0         | 0   |
| HER2/neu+               | 25        | 25  |
| Triple positive         | 1         | 1   |
| Triple negative         | 20        | 20  |
| Total                   | 100       | 100 |

R+/PR+(52%) were the commonest hormone receptor expression followed by HER2/neu(25%) and triple negatives(20%). (Table 2) (Fig 2). Most of the breast carcinomas encountered was in stage 2 (57%). The remaining were in stage 1 (28%) and stage 3 (15%).(Table 3)

Table 3: Pathological Staging of breast carcinoma

| Stage | Frequency | %   |
|-------|-----------|-----|
| 1     | 28        | 28.0|
| 2     | 57        | 57.0|
| 3     | 15        | 15.0|
| 4     | 0         | 0   |
| Total | 100       | 100.0|

Fig 2: IHC photographs showing nuclear stain positivity for estrogen receptor (a) Allred score-8 (10x) Inset showing internal control, (b) Allred score-8 (40x) (c) Allred score-8 (40x) And (d) IHC cytoplasmic membrane stain positivity for Her2/neu receptor-score-3+ (40x)

In the present study no significant correlation was obtained between the age of the patients with breast carcinoma and Hormone receptor status by IHC. (Table 4) (p>0.05). However significant association was seen among histologic grading and hormone receptor status wherein, 78.9% of grade 1 were ER+/PR+, 64.9% of grade 2 were also ER+/PR+ and 62.9% grade 3 were triple negative breast carcinoma. (Table 5) (p< 0.001). No significant correlation was obtained between stage of breast carcinoma and IHC hormone receptor status (Table 6) (p>0.05)

Table 4: Association of IHC hormone receptor status with AGE of the patients with breast carcinoma

| IHC hormone receptor status | <50 YEARS (%) | >50 YEARS (%) |
|----------------------------|---------------|---------------|
| ER+/PR+                    | 41(51.3)      | 11(55)        |
| ER+/PR-                    | 2(2.5)        | 0             |
| ER-/PR+                    | 0             | 0             |
| HER2/neu+                  | 20(25)        | 5(25)         |
| Triple Positive            | 1(1.2)        | 0             |
| Triple Negative            | 16(20)        | 4(20)         |
| Total                      | 80            | 20            |

Table 5: Association of IHC hormone receptor status with Grade of the tumor

| IHC hormone receptor status | GRADE 1 (%) | GRADE 2 (%) | GRADE 3 (%) |
|-----------------------------|-------------|-------------|-------------|
| ER+/PR+                     | 15(78.9)    | 35(64.9)    | 2(7.4)      |
| ER+/PR-                     | 1(5.3)      | 1(1.8)      | 0           |
| ER-/PR+                     | 0           | 0           | 0           |
| HER2/Neu+                   | 3(15.8)     | 15(27.8)    | 7(26.4)     |
| TP                           | 0           | 0           | 1(3.3)      |
| TN                           | 0           | 3(5.5)      | 17(62.9)    |
| Total                        | 19(100)     | 54(100)     | 27(100)     |
Table 6: Association of IHC hormone receptor status with stage of the patients with breast carcinoma

| IHC Hormone receptor status | Stage 1(%) | Stage 2(%) | Stage 3(%) | Stage 4(%) |
|-----------------------------|-----------|-----------|-----------|-----------|
| ER+/PR+                     | 12(42.9)  | 31(54.4)  | 9(60)     | 0         |
| ER+/PR-                     | 2(7.1)    | 0         | 0         | 0         |
| ER-/PR+                     | 0         | 0         | 0         | 0         |
| HER2/Neu                    | 7(25)     | 14(24.6)  | 4(26.8)   | 0         |
| Triple Positive             | 0         | 0         | 1(6.6)    | 0         |
| Triple Negative             | 7(25)     | 12(21)    | 1(6.6)    | 0         |
| TOTAL                       | 28        | 57        | 15        | 0         |

4. Discussion

The conventional prognostic factors for breast carcinoma include age, tumor grade, histological type, stage and hormone receptor status for estrogen, progesterone receptors and Her2/neu overexpression [4-13].

Age range among Indian breast cancer patients is found to be lower when compared to the Western countries with an average difference of one decade. This is likely to be due to the different age distribution of the Indian population, where only 7% of the population is above the age of 60 years [2-9]. In the present study 49% of women were in the age group of 41-50 years, in contrast a study by Pakseresht et al [9] had lower age range from 31-40 years (34.5%), whereas Ambroise et al [6](46.4%)

| Grade of The Tumor | Azizun-Nisa et al, 2008[7] | Adedayo et al 2009[12] | Suvarchala et al 2011[8] | Ambroise et al 2011[6] | Ghosh et al 2011[5] | Present study 2014 |
|--------------------|-----------------------------|------------------------|--------------------------|------------------------|---------------------|---------------------|
| 1                  | 6.7                         | 21.2                   | 28.12                    | 9.4                    | 0.3                 | 19                  |
| 2                  | 55.3                        | 38.4                   | 42.18                    | 57.3                   | 15.9                | 54                  |
| 3                  | 38.0                        | 35.9                   | 29.69                    | 33.3                   | 75.4                | 27                  |

Immunohistochemistry revealed 52% ER+/PR+, 25% Her2/neu positivity and 20% of triple negatives. These results were in concordance with other Indian studies having lowered positive receptors and higher Her2/neu expression and triple negatives [4-6,8]. However western literature showed higher positive receptor status and lower triple negatives and Her2/neu [7,10,12,14].

| Hormone receptor status | Aidedayo et al 2009[12] | Sharif et al 2010[14] | Suvarchala et al 2011[8] | Ambroise et al 2011[6] | Ghosh et al 2011[5] | Present study 2014 |
|-------------------------|-------------------------|-----------------------|-------------------------|------------------------|---------------------|---------------------|
| ER+/PR+                 | 68.9                    | 62.8                  | 32.8                    | 47                     | 51.2                | 52                  |
| ER+/PR-                 | -                       | 11.8                  | 14.0                    | 1                      | 2                   | 2                   |
| ER-/PR+                 | -                       | 4.1                   | 10.94                   | 0                      | 0                   | 0                   |
| HER2/Neu+               | 7.5                     | 28.1                  | -                       | 27                     | 24.8                | 25                  |
| Triple positive         | 10.2                    | -                     | -                       | -                      | 1                   | 1                   |
| Triple negative         | 13.4                    | -                     | 42.19 (ER-/PR-)         | 25                     | 29.8                | 20                  |

Staging of breast carcinomas showed higher in stage 2 accounting to 57% followed by stage 1(28%) and stage 3(15%) in concordance with other Indian studies [15,16]. In western countries stage 1(56.4%) are the majority followed by stage 2 and 3 possibly due to increased awareness and rampant breast cancer screening programs [12,17].

In the present study correlation between hormone receptor status with patients’ age, grade of the tumor and stage of breast carcinoma were carried out. No statistical significance was found between patient’s age and stage. Literature reveals ER positivity increases with age, that is elderly aged patients express more estrogen receptors [5,7,8,12]. PR positivity does not show any correlation with age[6,7]. Whereas younger patients have breast carcinomas with triple negative phenotype compared to the elderly [5,18]. Studies reveal no correlation between patients age and Her2/neu expression similar to our study except for one study by Ambroies et al showed that Her-2/neu expression decreased with age [6,7,19].

| Grade of The Tumor | Azizun-Nisa et al, 2008[7] | Adedayo et al 2009[12] | Suvarchala et al 2011[8] | Ambroise et al 2011[6] | Ghosh et al 2011[5] | Present study 2014 |
|--------------------|-----------------------------|------------------------|-------------------------|------------------------|---------------------|---------------------|
| 1                  | 6.7                         | 21.2                   | 28.12                   | 9.4                    | 0.3                 | 19                  |
| 2                  | 55.3                        | 38.4                   | 42.18                   | 57.3                   | 15.9                | 54                  |
| 3                  | 38.0                        | 35.9                   | 29.69                   | 33.3                   | 75.4                | 27                  |
Table 9: Comparison of Hormone receptor status with Age of the patients with Breast carcinoma

| Study                      | AGE          | Hormone receptor status |
|----------------------------|--------------|-------------------------|
| Azizun-nisa et al 2008 [7] | >50 years    | ER+ PR+ HER2/neu         |
| Adedayo et al 2009 [12]   | >60 years    | ER+/PR+                 |
| Vaidyanathanet al 2010 [19]| No correlation| HER2/neu                |
| Ambroise et al 2011 [6]   | >65 years    | ER+ PR+ HER2/neu        |
| Ghosh et al 2011 [5]      | >70 years    | ER+/PR+ Triple negatives|
| Patil et al 2001[18]      | <35 years    | Triple negatives        |
| Present study 2014         | No correlation | ER,PR,HER2/neu          |

In the present study significant correlation was established between ER/PR hormone receptor status and grade of the tumor. 78.9% of grade 1 and 64.9% of grade 2 were ER+/PR+ and 62.9 % grade 3 tumors were triple negatives. This was in concordance with other Indian and western literatures [6,7,8,12,19-25]. In the present study no significant correlation was seen between Her2/neu and tumor grade similar to other studies except for a study by Ambroise et al wherein he concluded Her2/neu overexpressed tumors are grade 3 [6,7,19,26](Table 10)

Table 10: Comparison of Hormone receptor status with Grade of the tumor

| Study                      | Grade Of Tumor | Hormone Receptor Positive |
|----------------------------|----------------|---------------------------|
| Azizun-nisa et al 2008 [7] | Grade1         | 70% ER+/PR+ Her2/neu      |
| Adedayo et al 2009 [12]   | Grade 1&2 Grade 3 | 28.9% & 44.9% ER+/PR+ 76.3% triple negatives |
| Vaidyanathanet al 2010 [19]| No correlation | Her2/neu                  |
| Ambroise et al 2011 [6]   | Grade 1 Grade 3 | ER+/PR+ Her2/neu Triple negatives |
| Suvarchala et al 2011[8]  | Grade 2        | 51.85% ER+/PR+            |
| Present study 2014         | Grade 1 Grade 3 | 78.9% ER+/PR+ 62.9% Triple negatives |

Very few studies have compared hormone receptor expression and stage of the breast carcinoma and revealed that patients with ER, PR positive present with early stage breast carcinoma [12,17]. Her2/neu receptor showed no correlation with the staging [27]. However in the present study no significant correlation was established between all three receptors and the stage of breast carcinoma. (Table 11)

Table 11: Comparison of Hormone receptor status with Staging of Breast carcinoma

| Study                      | Stage | Hormone Receptor Status |
|----------------------------|-------|-------------------------|
| Adedayo et al 2009 [12]   | Stage 1 | ER+/PR+                |
| Vaidyanathanet al 2010 [19]| No correlation | Her2/neu                |
| Rai et al 2010 [17]       | Stage 1 | ER+                     |
| Present study 2014         | No correlation | ER,PR,HER2/neu          |

5. Conclusion

Majority of tumours of grade 1 were ER, PR positive and majority of grade 3 tumours were triple negatives which exemplifies the fact that higher the grade, lower is the hormone receptor expression. This study highlights the importance of grading and hormone receptor status evaluation. Grading highly correlates with the survival rate and receptor status predicts the response to hormonal therapy. Histopathological grading put together with receptor status offers an excellent method of correlation of survival rate and response to hormonal therapy. This lightens up a prospect of various treatment modalities for the needful.

References

[1] National Cancer Registry Programme, Indian Council of Medical Research. Leading sites of cancer. In, Consolidated Report of Population Based Cancer Registries 2001-2004, Incidence and Distribution of Cancer. Bangalore: Coordinating Unit, National Cancer Registry Programme (ICMR). 2006; 8-30.

[2] Nandakumar A, Ramnath T, Chaturvedi M. The magnitude of cancer breast in India: a summary. Indian J Surg Oncol. 2010; 1:8-9.
Histopathological Grade Versus Hormone Receptor Status In Breast Carcinoma

Murthy NS, Chaudhry K, Nadayil D, Agarwal UK, Saxena S. Changing trends in incidence of breast cancer: Indian scenario. Indian J Cancer 2009; 46:73.

Shet T, Agrawal A, Nadkarni M, Palkar M, Havaladar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral centre in India: What was and what is. Indian J Pathol Microbiol 2009; 50:284-90.

Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P et al. Estrogen, progesterone and HER2 receptor expression in breast tumors of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer 2011; 48:391-6.

Ambroise M, Ghosh M, Mallikarjuna VS, Kurian A. Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India Immunohistochemical Profile of Breast Cancer Patients at a Tertiary Care Hospital in South India. Asian Pacific J Cancer Prev 2011; 12:625-629.

Azizun-Nisa, Bhurgri Y, Raza F, Kayani N. Comparison of ER, PR and HER-2/neo (C-erb B 2) reactivity pattern with histologic grade, tumor size and lymph node status in breast cancer. Asian Pac J Cancer Prev 2008; 9:553-6.

Suvarchala SB, Nageshwararao R. Carcinoma Breast Histopathological and hormone receptors correlation. J Biosci Tech 2011;2: 340-48.

Pakseresht S, Ingle G K, Bahadur A K, Ramteke V K, Singh M M, Garg S, Agarwal P N. Risk factors with breast cancer among women in Delhi. Indian J Cancer 2009; 46:132-8.

Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol. 2000; 53: 688-96.

Sandhu DS, Sandhu S, Karwasra RK, Marwah S. Profile of breast cancer patients at a tertiary care hospital in north India. Indian J Cancer 2010; 47:16-22.

Adeayo AO, Engel JM, Greenlee RT, Mukesh BN. Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinopathologic Features and Survival. Clin Med Res. 2009; 7: 4–13.

Aryandono T, Harijadi, Soeripto. Hormone receptor status of operable breast cancers in Indonesia: correlation with other prognostic factors and survival. Asian Pac J Cancer Prev2006; 7: 321-4

Sharif MA, Mamoon N, Mushtaq S, Khadim MT, Jamal S. Steroid Hormone Receptor Association with Prognostic Markers in Breast Carcinoma in Northern Pakistan. J Coll Physicians Surg Pak. 2010; 20: 181-85.

Chopra R. The Indian Scene. J Clin Oncol. 2001; 19:106-111.

Kuraparthi S, Reddy KM, Yadagiri LA, Yutla M, Venkata PB, Reddy RPV. Epidemiology and patterns of care for invasive breast carcinoma at a community hospital in Southern India. World J Surg Oncol. 2007; 5:56

Goyanes RIA, Perez XE, Rodriguez RC, Lopez MO, Odio SF, Fernandez LL, Yi MG, Padilla CR. Hormone Receptors and Other Prognostic Factors in Breast Cancer in Cuba. MEDICC Review, 2010; 12: 36-40.

Patil VW, Singhai R, Patil AV, Gurav PD. Triple-negative (ER, PgR, HER-2/neu) breast cancer in Indian women. Breast Canc Targ Ther. 2011; 3: 9–19.

Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. ErbB- 2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer. 2010; 47: 8-15.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano. Descriptive analysis of Estrogen Receptor(ER)-Negative, Progesterone Receptor (PR)-Negative, and HER2-Negative Invasive Breast Cancer, the so-called Triple-Negative Phenotype. Cancer 2007; 109:1721-8.

Munjal K, Ambaye A, Evans MF, Mitchell J, Nandedkar S, Cooper K. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in Infiltrative Breast Carcinomas in Indian Patients. Asian Pac J Cancer Prev 2009; 10: 773-78.

Maynard PV, Davies CJ, Blamey RW. Relationship between oestrogen-receptor content and histological grade in human primary breast tumours. Br J Cancer.1978; 38: 745-8.

Kakarala M, Rozek L, Cote M, Liyanage S, Brenner DE. Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the US- a SEER analysis. BMC cancer. 2010; 10:191.

Rakha EA, El-Sayed ME, Green AR. Prognostic markers in triple negative breast cancer. Cancer 2007; 109:25–32.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403–410.

Naem M, Nasir A, Aman Z, Ahmad T, Samad A. Frequency of Her-2/neu receptor positivity and its association with other features of breast cancer. J Ayub Med Coll Abbottabad2008; 20(3):23-26.

Lund MJ, Butler EN, Bumpers HL,Okoli J, Rizzo M, Hatchett Net al. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008; 113: 608-15.